Simulation of tumor-induced angiogenesis and its response to anti-angiogenic drug treatment: Mode of drug delivery and clearance rate dependencies

Journal of Cancer Research and Clinical Oncology

Volumn 130, Issue 1, 2004, Pages 15-24

  Tee, Daniel ^a   DiStefano III, Joseph ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiostatin; Dosing; Endostatin; Endothelial cell; Heparan; Mathematical model

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ENDOSTATIN;

ANGIOGENESIS; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; DEGRADATION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG INFUSION; ENDOTHELIUM CELL; KINETICS; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MOUSE; NONHUMAN; NONLINEAR SYSTEM; PRIORITY JOURNAL; SIMULATION; STOCHASTIC MODEL; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANGIOSTATINS; ANIMALS; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; ENDOSTATINS; HUMANS; MATHEMATICAL COMPUTING; MODELS, THEORETICAL; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0742304073     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-003-0491-1     Document Type: Article

References (26)

1. Anderson ARA, Chaplain MAJ (1998) Continuous and discrete mathematical models of tumor-induced angiogenesis. Bull Math Biol 60:857-900
2. Carmeliet P, Collen D (1997) Molecular analysis of blood vessel formation and disease. Am J Physiol 273 [Heart Circ Physiol 42]:H2091-H2104
3. Chaplain MAJ, Stuart MA (1993) A model mechanism for the chemotaxis response of endothelial cells to tumor angiogenesis factor. IMA J Math Appl Med Biol 10:149-168
4. Drixler TA, Rinkes IH, Ritchie ED, van Vroonhoven TJ, Gebbink MF, Voest EE (2000) Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res 60:1761-1765
5. Folkman J, Klagsbrun M (1987) Angiogenic factors. Science 235:442-447
6. Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285
7. Gimbrone MA, Cotran RS, Leapman SB, Folkman J (1974) Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst 52:413-427
8. Griffioen AW, Molema G (2000) Angiogenesis: potentials for pharmacological intervention in the treatment of cancer, cardiovascular diseases and chronic inflammation. Pharmacol Rev 52:237-268
9. Ingber D (1990) Fn controls capillary endothelial cell growth by modulating cell shape. Proc Natl Acad Sci 87:3579-3583
10. Hu T-M, Hayton WL (2001). Allometric scaling of xenobiotic clearance: uncertainty versus universality. AAPS PharmSci 2000 3:1-14
11. Lauffenberger D, Aris R, Kennedy CR (1984) Travelling bands of chemotactic bacteria in the context of population growth. Bull Math Biol 46:19-40
12. Liu D, Shriver Z, Venkataraman G, El Shabrawo Y, Sasisekharan R (2002) Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. PNAS 99: 568-573
13. McDougal SR, Anderson ARA, Chaplain MAJ, Sheraratt JA (2002) Mathematical modelling of flow through vascular networks: implication for tumour-induced angiogenesis and chemotherapy strategies. Bull Math Biol 64:673-702
14. Molema G, Van Veen-Hof I, Van Loenen-Weemaes A, Proost JH, De Leu LFMH, Meijer DKF (2001) Pharmacokinetics and whole body distribution of elastase derived angiostatin (K1-3) in rats. Int J Cancer 91:1-7
15. Mundhenke C, Thomas JP, Wilding G, Lee FT, Kelzc F, Chappell R, Neides R, Sebree L, Friedl A (2001) Tissue examination to monitor antiangeogenic therapy. Clin Cancer Res 7:3366-3374
16. Muthukkaruppan VR, Kubai L, Auerbach R (1982) Tumor-induced neovascularization in the mouse eye. J Natl Cancer Inst 69:699-705
17. Novak K (2002a) Angiogenesis inhibitors revised and revived at AACR. Nature 8:427
18. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth, Cell 88:277-285
19. Olsen L, Sherratt JA, Maini PK, Arnold F (1997) A mathematical model for the capillary endothelial cell-extracellular matirix interactions in wound-healing angiogenesis. IMA J Math App Med Biol 14:261-281
20. Orme ME, Chaplain MAJ (1996). A mathematical model of the first steps of tumor-related angiogenesis: capillary sprout formation and secondary branching. IMA J Math App Med Biol 13:73-98
21. Orme ME, Chaplain MAJ (1997) Two-dimensional models of tumor angiogenesis and anti-angiogenesis strategies. IMA J Math App Med Biol 14:189-205
22. Rehn M, Veikkola T, Kukk-Valdre E, Nakamura H, Ilmonen M, Lombarde C, Pihlajaniemi T, Alitalo K, Vuori K (2001) Interaction of endostatin with integrins implicated in angiogenesis. PNAS 98:1024-1029
23. Sasaki T, Larsson H, Kreuger J, Salmivirta M, Claesson-Welsh L, Lindahl U, Hohenester E, Timpl R (1999) Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin. EMBO J 18:6240-6248
24. Sharma A, Jusko, WJ (1998) Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br J Clin Pharmacol 45:229-239
25. Sim BKL, MacDonald NJ, Gubish ER (2000) Angiostatin and endostatin: endogenous inhibitors of tumor growth. Cancer Metastasis Rev 19:181-190
26. Thomas, JP, Schiller J, Lee F, Perlman S, Friedl A, Winter T, Marnocha R, Arzoomanian R, Alberti D, Binger K, Volkman J, Feierabend C, Tutsch K, Dresen A, Auerbach R, Wilding G (2000) A phase I and pharmacokinetic study of recombinant human endostatin. In: Proc 11th NCI-EORTC-AACR Symp 95:2000. Clin Cancer Res 6[Suppl]